Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative
US11278555B2 · kind B2 · utility
0Cited by
1References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 10, 2017 |
| Grant date | Mar 22, 2022 |
| Priority date | — |
| Expiry date | Apr 10, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.